Sun Pharmaceutical Industries
About Sun Pharmaceutical Industries
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.
Recent News
Sun Pharma to Acquire Organon for ~$11.75B
Sun Pharma to Acquire Organon for $11.75 Bn, Marking India's Largest Overseas Pharma Deal
Nifty Holds Near 24,000, Sensex Above 76,200 at Midday; Eicher Motors, Wipro Lead Gains
Blue Owl Expands Real Estate with Sila Realty Acquisition – Merger Arbitrage Mondays
Editorial. Costly Remedy
C&EN Weekly Chemistry News Quiz, May 1
Semaglutide Race: Torrent Grabs 38% Market Share
New AAD Leaders Aim to Fix ‘Broken’ Access to Care, Serve Next Generation of Dermatologists
Sun Pharma Explores Funding Mix for $12 Billion Organon Deal
SBI in $1 Billion Funding for Sun Pharma’s US Deal
Pharma and Biotech M&As 2026 Deal Watcher
Stock Market Highlights: Sensex, Nifty Rebound, Snap Three-Day Losing Streak on IT, Sun Pharma Rally
India-Based Companies Announce a Record $20B Worth of US Investments
Dilip Shanghvi-Led Sun Pharma's Most Expensive M&A Deal Signals Fading Allure of US Generics Business
Sun Pharma to Acquire Organon for $12 Billion, Its Largest U.S. Deal Yet
Bernstein Forecasts India’s Biopharma Market to Hit $195 Bn by 2035 on Innovation Surge
Citi CEO Jane Fraser Accelerates Cultural Overhaul with New Executive Team
Stocks to Buy or Sell for Short Term: Religare Broking's Ajit Mishra Suggests Strategies for 3 Shares
India's Sensex Drops 1,082 Points as Oil Prices Surge and Modi Calls for Austerity
Sun Pharma Q4 Net Profit up 26 per Cent
Sun Pharma to Acquire Organon for $11.75 Billion, Expanding B2B Drug Portfolio
Generally Good Indian Pharma Companies
India’s Pharma Industry Is Going Global. But Can It Catch up to China?
How Big Is Organon’s Biosimilar Push for Sun Pharma?
Generally Good Indian Pharma Companies
VIDEO: ‘New Era of Oral Therapies’ on Horizon in Psoriasis
Top Biotech Deals in April 2026
FDA Expands Tremfya’s Label in Psoriatic Arthritis
Sun Pharma to Acquire Organon for $11.75 B, Boosting Women’s Health and Biosimilars
Treating Cancer Based on Mutation Alone Does Not Improve Survival
Morning Brief Podcast: Sun–Organon: The Scope, Risks, and Future of India's Biggest Pharma Deal
Zaynich's Blockbuster Potential Lifts Wockhardt's Long-Term Outlook
Asia Is Quietly and Quickly Buying up America
Nifty Snaps Three-Day Losing Streak, Climbs 195 Points; Midcaps Lead the Charge
Sun Pharma Recalls Cancer Drug After Finding Glass Particles in some Vials